Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :


By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :


Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Algernon Pharma’s Lead NASH Compound Shows Fibrosis Reduction

Stockhouse Editorial
1 Comment| April 1, 2019

Clinical stage pharmaceutical development Company Algernon Pharmaceuticals Inc. (CSE: AGNOTCQB: BTHCFForum) stated Monday that one of its lead compounds for non-alcoholic steatohepatitis - NP-135 - demonstrated a 34.6 per-cent reduction of a key secondary marker of fibrosis, liver hydroxyproline. This is in addition to being metabolically neutral in a number of important measurements.

For more, click here.

The Company recently announced that leading global expert and clinician in the area of chronic liver disease, Dr. Arun Sanyal, has joined its Medical and Scientific Advisory Board.

FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.

Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Metals & Mining

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to access this feature.


Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.